280results about "Protease inhibitors" patented technology

The invention relates to the technical field of coating surface preparation, in particular to an anticoagulant coating based on novel tick-derived anticoagulant protein Qinghaenin and a preparation method of the anticoagulant coating. The functional layer of the anticoagulant coating comprises the following components: anticoagulant protein Qinghaenin or a functional peptide fragment Qinghaenin 167-192 of the anticoagulant protein Qinghaenin, wherein the amino acid sequence of the functional peptide fragment is as shown in SEQ ID NO. 2. The preparation method of the anticoagulant coating comprises the following steps: by using a polydopamine coating as a substrate layer, covalently grafting through an amido bond, immobilizing anticoagulant protein Qinghaenin capable of inhibiting FXII factor activation or a functional peptide fragment Qinghaenin 167-192 thereof on the surface of a medical polymer material, and successfully constructing a novel anticoagulant coating. Compared with an unmodified medical polymer material, the modified coating can significantly enhance the hydrophilic performance of the material and inhibit platelet adhesion and activation, finally effectively prolongs the in-vitro blood coagulation time, and shows excellent anticoagulation performance.

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

The invention belongs to the technical field of biology, and particularly discloses a high-temperature-resistant antibacterial protein Cystatin B sourced from marine fish as well as a preparation method and application of the high-temperature-resistant antibacterial protein Cystatin B. The high-temperature-resistant antibacterial protein Cystatin B is derived from pomfret, and the amino acid sequence of the high-temperature-resistant antibacterial protein Cystatin B is as shown in SEQ ID NO. 1; the nucleotide sequence of the gene for coding the high-temperature-resistant antibacterial protein Cystatin B is as shown in SEQ ID NO.2, and the sequences of primers adopted for cloning the gene are as shown in SEQ ID NO.3-4. The high-temperature-resistant antibacterial protein Cystatin B has a remarkable antibacterial effect on gram-negative bacteria such as escherichia coli, vibrio parahaemolyticus and edwardsiella tarda as well as gram-positive bacteria such as staphylococcus aureus; and after being treated at the temperature of 100 DEG C, the antibacterial agent still can keep relatively high antibacterial activity. The antibacterial protein is simple in preparation method, can replace traditional antibiotics, and can quickly and efficiently prevent and treat various common bacterial diseases in aquaculture.

The invention discloses a medicago sativa MsKTI3 gene and application of the medicago sativa MsKTI3 gene in improving the salt tolerance of plants, a candidate gene MsKTI3 related to the salt tolerance of medicago sativa is screened out through transcriptome sequencing analysis, the MsKTI3 is cloned, the medicago sativa and arabidopsis thaliana are over-expressed, and the functions of the gene are identified. According to the invention, a foundation is laid for deeply researching functions and a salt-tolerant regulation mechanism of MsKTI3, and a candidate gene resource is also provided for improving salt-tolerant molecules of alfalfa.

The invention belongs to the field of biological medicines, and discloses an application of a protein polymer in preparation of a medicine for treating Alzheimer's disease, a production process of the protein polymer comprises the following steps: S1) using ultraviolet irradiation to stimulate mesenchymal stem cells and culturing; and S2) splitting the mesenchymal stem cells, separating and purifying to obtain the protein polymer. According to the present invention, the mesenchymal stem cells are stimulated to express the protein with the nerve repair function through the ultraviolet irradiation stress mode, and the protein polymer is obtained through further separation and purification, such that the protein polymer can be adapted to diversified application modes, can improve the abnormal conditions of the Alzheimer's disease related biomarkers, and can provide the significant treatment effect on the Alzheimer's disease.

Disclosed herein are topical compositions for treating wounds. The topically compositions include a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide. Also disclosed are methods of treating a wound in subject. The methods include administering a topical formulation that includes a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide to the wound.

The invention belongs to the field of biological medicines, and discloses an application of a protein polymer in preparation of a medicine for treating spinal cerebellar ataxia disease, a production process of the protein polymer comprises the following steps: S1) using ultraviolet irradiation to stimulate mesenchymal stem cells and culturing; and S2) splitting the mesenchymal stem cells, separating and purifying to obtain the protein polymer. An ultraviolet irradiation stress mode is adopted, mesenchymal stem cells are stimulated to express protein with a neural repair function, the protein polymer is obtained through further separation and purification, the cell gene expression pathway is regulated, the cell stress state is relieved, the cells are promoted to recover normal forms and functions, meanwhile, the preparation mode is relatively simple, and the preparation method is suitable for large-scale production. And quality and yield monitoring is facilitated, and the method can be adapted to diversified application modes.

The invention provides a chemical synthesis method of a TIMP2 protein N-terminal structural domain. An amino acid sequence of an N-terminal structural domain of TIMP2 protein is divided into four segments, the four segments are synthesized by a solid-phase polypeptide synthesis method, full-length linear polypeptide is obtained through natural chemical connection, sulfur removal and sulfydryl removal and acetamino methyl removal, finally impurities in a system are removed, the full-length linear polypeptide is dropwise added into a refolding reaction system, oxidation and refolding reactions are carried out, and the TIMP2 protein is obtained. A target product is obtained. The N-TIMP2 of the N-terminal structural domain of the TIMP2 retains the inhibitory activity of the TIMP2 on the MMP14, the N-TIMP2 obtained through chemical total synthesis can introduce non-natural amino acid to any site in the sequence or perform specific modification or mutation in the synthesis process, an effective tool is provided for researching the specific action mechanism of the N-TIMP2 and the MMP14, and a foundation is further laid for research and development of the MMP14 inhibitor.

Urinastatin glycoforms, urinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing and treating diseases, are provided. Embodiments of the present disclosure include an isolated mature urinastatin polypeptide comprising: (i) an O-linked glycosylation site modified with residues Glu-Gly-Ser-Gly (SEQ ID NO: 10) to reduce glycosylation at the O-linked glycosylation site; (ii) an N-linked glycan at residue N45; and (iii) an O-linked glycan at residue T17, a residue defined by SEQ ID NO: 2 or 4, wherein the urinastatin polypeptide has at least one urinastatin activity.

Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.

The present disclosure relates generally to methods of preventing or inhibiting neutrophil extracellular trap (NET) formation and methods of treating a disease or disorder associated with NET formation in a subject.

The invention relates to the technical field of genetic engineering, in particular to a construction method and culture of a recombinant hirudin expression vector with algae as chassis cells. An endogenous promoter beta2-tubulin and an RBCS2 intron sequence form a key starting element, the key starting element is linked with a Hygromycin resistance gene, a 2A peptide self-cleavage sequence is added between a recombinant hirudin gene and the Hygromycin resistance gene, and the tail end is connected with an HA tag to construct the algae expression vector. In order to improve the safety and synthesis yield of the recombinant hirudin and reduce the production cost, the invention successfully constructs an algae expression vector for expressing the recombinant hirudin; the expression vector can significantly improve the activity and yield of recombinant hirudin.

The invention relates to a method for preserving or re-conditioning a transplant by administering recombinant alpha1-antitrypsin (AAT) protein or fragment thereof, expressed in a genetically modified yeast, to said transplant during ex vivo normothermic perfusion prior to transplantation in a subject. Another aspect of the invention relates to a method for preventing and / or reducing ischemic-reperfusion injury (IRI) of a transplant by administering recombinant alpha1-antitrypsin (AAT) protein or a fragment thereof, expressed in a genetically modified yeast, during ex vivo normothermic perfusion of the transplant prior to transplantation in a subject. A further aspect of the invention relates to a preserved transplant, obtainable by the methods of the invention. A further aspect of the invention relates to a perfusate or kit for preserving a transplant, wherein said perfusate comprises AAT or a fragment thereof expressed in a genetically modified yeast.

The present invention provides a novel antigen for soy allergy, a method and kit for diagnosing soy allergy, a pharmaceutical composition containing the antigen, soybeans or soybean products from which the antigen has been removed, and a tester for determining the presence or absence of soybean antigen in a target object. [Solution] The diagnostic kit of the present invention comprises at least one of the proteins identified as (1) to (8), or at least one of the proteins identified as (1α) to (55α).

The specification relates to a method of manufacturing a diabetic foot patient-specific skin regeneration sheet, and a diabetic foot patient-specific skin regeneration sheet.

The present application relates to the field of biomedical detection, specifically to a SPINK1 specific ELISA detection kit for aging detection, the kit contains polyclonal antibodies specific to SPINK1 protein and a color developing reaction system for assisting detection; the kit is also configured with E. coli derived recombinant SPINK1 protein with a purity of more than 99% as a standard for concentration calibration; the specific reagent list supplied in the kit includes horseradish peroxidase labeled antibody, blocking solution, washing buffer, the color developing reaction system is composed of 3,3',5,5'-tetramethylbenzidine solution, and the termination solution for interrupting the color developing chemical reaction is independently packaged. Through prokaryotic expression technology and targeted optimization of core induction conditions, combined with protein affinity chromatography purification process based on imidazole elution mechanism, the present application successfully realizes high-efficiency soluble expression of SPINK1 protein in E. coli vector and obtains recombinant protein with a purity of more than 99%.

Provided is a technology for substituting egg white in a food product. Serpins derived from plants or fungi are utilized to substitute egg white in a food product.

The present disclosure provides a method of making a site-specific antibody to a target of interest.

Compositions and methods for expressing alpha 1 antitrypsin (AAT) in a host cell are provided. Also provided are compositions and methods for treating subjects having alpha 1 antitrypsin deficiency (AATD).

Of the present technology are SERPIN peptide derivatives, methods of making the same, and uses of the same for treating various conditions associated with LRP1 mediation.

The present application relates to a fibroblast activation protein ligand and a use thereof, and in particular to a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, and a use thereof in diagnosis or treatment of diseases related to a fibroblast activation protein, such as tumours or cancers.

Therapeutic mRNA molecules are provided that are expressible to provide a target polypeptide or protein.SOLUTION: The RNA molecule can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided is a DNA template that can be transcribed to provide a target mRNA and that can have altered nucleotides such as reduced deoxyadenosine. The present invention also provides a process for producing a therapeutic mRNA molecule. An RNA molecule can be translated in vitro or in vivo to provide an active polypeptide or protein.SELECTED DRAWING: Figure 1

An object to be achieved by the present invention is to provide a novel γ-secretase inhibitor including, as an active ingredient, a substance whose γ-secretase inhibitory activity has heretofore been unknown. The present invention provides a γ-secretase inhibitor including a three-finger toxin.

Aspects of the present disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBD"), such as ulcerative colitis ("UC") and / or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an outer surface of the core. In some cases, the protease inhibitor is a gligliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and / or small intestine of a subject administered the pharmaceutical dosage form. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., bacterial protease) to the large intestine (e.g., colon) and / or the small intestine of a subject.

The present application relates to the technical field of new materials, in particular to a porous ulinastatin adsorbent with a responsive shell and a preparation method thereof.The porous ulinastatin adsorbent with a responsive shell is a full-synthetic polymer matrix, and has a solid structure.A high-crosslinking-degree polyvinyl alcohol / styrene / divinylbenzene core and a MOF nanoparticle-enhanced framework endow the porous ulinastatin adsorbent with a responsive shell with excellent mechanical strength, and the porous ulinastatin adsorbent with a responsive shell can withstand the pressure in an industrial chromatography column and is not prone to breakage.Because both recognition and desorption are physical processes, the replacement frequency and overall cost of the porous ulinastatin adsorbent with a responsive shell in the production process are greatly reduced, and a reliable guarantee is provided for industrial large-scale and continuous production.

The present invention relates to polypeptides comprising gigastasin variants in which one or more residues have been substituted compared to the naturally occurring gigastasin of the giant Amazon leech. It further relates to processes for their production, to their lectin pathway inhibition, to their half-life extension, and to their therapeutic use.

The present invention relates to a cathepsin K inhibitor comprising or consisting of Formula (I) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (I), wherein (X1) is the amino acid K; (X2) is an amino acid selected from R and W, and is preferably R; (X3) is an amino acid selected from R and W, and is preferably R; (X4) is the amino acid L; (X5) is an amino acid selected from Y, V and W, and is preferably V or Y, and is most preferably V; (X6) is an amino acid selected from I, M, L, W and R, and is preferably I, L or W; and is most preferably I; (X7) is an amino acid selected from H, W, A T, R; and is preferably H or R, and is most preferably R; and (Y) is a Michael acceptor. The present invention also relates to a cathepsin L inhibitor comprising or consisting of Formula (II) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (II), wherein (X1) is the amino acid K; (X2) is the amino acid R; (X3) is an amino acid selected from R, L and M, and is preferably L; (X4) is an amino acid selected from L, W, F and Y, and is preferably W; (X5) is an amino acid selected from V, H and R, and is preferably V; (X6) is an amino acid selected from M, L, I, W and R, and is preferably L; (X7) is an amino acid selected from W, A T, R; and is preferably W; and (Y) is a Michael acceptor.

The present invention provides specific matrix metalloproteinase (MMP) polypeptide inhibitors and uses thereof in treating MMP-related diseases, in particular cancer, such as breast cancer and glioblastoma.